Audit: QRS - Sorbitol for Health & Longevity
Audit conducted on 21/08/2026 14:32 using AI4L / Opus 5
Summary
| Items | Count |
|---|---|
| Total | 93 |
| Passed | 83 |
| Failed | 0 |
| N/A | 10 |
| Pass Rate | 100.00% |
- Total = Passed + Failed + N/A
- Pass Rate = Passed / (Passed + Failed) × 100
- N/A items are excluded from the pass rate calculation
1. General Rules
| # | Description | Result | Comments |
|---|---|---|---|
| 1.1 | Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER. | 🟢 | Verified span by span against the ER: protocol cells vs ER lines 339/347/351, time cells vs line 394, benefits/risks vs the ER tier headings, gates vs lines 291-315, monitoring table vs lines 424-433, qualitative list vs lines 437-442. |
| 1.2 | Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing. | 🟢 | marker_8_target keeps the ER’s hedged wording verbatim (“No established consumer target; track change from the individual’s own baseline”). |
| 1.3 | The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”). | 🟢 | No strengthening or softening found; contraindication qualifiers (“stage 4 or worse”, “positive sorbitol breath test”, “reduced bowel motility”) are carried across intact. |
| 1.4 | The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc. | 🟢 | Nothing from Benefit-Modifying Factors or Risk-Modifying Factors is surfaced as a gate; the polystyrene sulfonate item is placed under Contraindications because the ER labels it “Absolute contraindication” (ER line 291). |
| 1.5 | PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact. | 🟢 | No PMIDs, NCT identifiers, author names, or brand names appear anywhere in the QRS; only generic drug names that are present in the ER. |
| 1.6 | The QRS does not introduce new attributions. | 🟢 | No attributions of any kind in the QRS. |
2. Focus, Tone & Audience
| # | Description | Result | Comments |
|---|---|---|---|
| 2.1 | The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing. | 🟢 | Matches the ER’s measured, evidence-weighted register. |
| 2.2 | The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging | 🟢 | Expert and data-driven; benefit tiers and monitoring targets give the reader actionable leverage. |
| 2.3 | The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor | 🟢 | States what the evidence shows rather than issuing instructions. |
| 2.4 | The QRS avoids language that implies medical or clinical advice | 🟢 | Descriptive throughout; the footer disclaimer is the template’s. |
| 2.5 | The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising” | 🟢 | Cells present the ER’s protocol as fact (“Split above 10 g daily”) rather than as advice. |
| 2.6 | The QRS never addresses “the reader” directly — it presents evidence, not guidance | 🟢 | No second-person pronouns anywhere in the document. |
| 2.7 | The QRS is written in plain language, avoiding unnecessary medical jargon | 🟢 | Plain language outside the biomarker names, which are the ER’s own terms. |
| 2.8 | Information is presented in a concise and very compact manner | 🟢 | Gate items, benefit and risk tiers are reduced to key facts; no ER prose is carried over. |
| 2.9 | It DOES NOT address the reader directly | 🟢 | Confirmed by search: no “you” / “your” in the file. |
| 2.10 | The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review. | 🟢 | Titration thresholds, breath testing and biomarker targets address a proactive, risk-aware reader. |
| 2.11 | The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort. | 🟢 | Presents breath testing, staged titration and repeat electrolyte panels without hedging on effort. |
| 2.12 | The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort. | 🟢 | Assumes willingness to titrate, measure and monitor. |
| 2.13 | Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience. | 🟢 | Weighting mirrors the ER: reliable laxative and glycaemic benefit against a predictable 10-20 g tolerance ceiling. |
| 2.14 | The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim. | 🟢 | No occurrence of “anti-aging”; the header frames the sheet as “Health & Longevity”. |
| 2.15 | The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “injection” not “shot”; “adverse event” not “bad reaction”). Direct quotes from sources are exempt. | 🟢 | Formal terminology in the document’s own voice (“osmotic diarrhea”, “co-administered oral medicines”, “malabsorption threshold”); the plainer At-A-Glance wording is the ER Conclusion text and is required by 7.4. |
3. Template Integrity
| # | Description | Result | Comments |
|---|---|---|---|
| 3.1 | The following labels and headings on the QRS are fixed and not modified: Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”; Gate headings: “Contraindications”, “Key Interactions”; Tier labels: “High”, “Medium”, “Low”, “Speculative”; Table column headers in Monitoring: “Marker”, “Target”, “Why” | 🟢 | All fixed labels verified in source: lines 445, 491, 535, 562, 583, 605, 634, 638-640, 758, plus the four tier labels. |
| 3.2 | All “…” from the [qrs_template] are present in the the QRS. | 🟢 | All 64 data-qrs-var spans present, in template order, from page_title through qualitative_item_6. |
| 3.3 | Spans that are not addressed in a checklist item are left unchanged | 🟢 | The three website=”…” spans (evidence_review, audit, full_review) and all template chrome are untouched. |
4. Formatting
| # | Description | Result | Comments |
|---|---|---|---|
| 4.1 | When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied” | N/A | N/A — no source ER section drawn on by the QRS is empty; every populated span has ER content. |
| 4.2 | Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label. | 🟢 | Protocol labels are the ER’s bold labels verbatim (“Standard laxative protocol”, “Single versus split dosing”, “Best time of day”); all eight caution items reuse the ER bold labels verbatim. |
| 4.3 | Labels are not paraphrased, abbreviated, or invented. | 🟢 | No paraphrasing; the three time labels derive directly from the ER’s single “Time to effect” bullet, which names laxative, dental and microbiome effects. |
| 4.4 | The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels. | 🟢 | Search for 🟩/🟥/🟨/⚠️ returns zero hits; tiers are carried by bold text labels and CSS. |
| 4.5 | The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page. | 🟢 | Content is condensed to labels and single-clause facts throughout; no section carries ER prose or spills a second sheet of content. |
5. Metadata
| # | Description | Result | Comments |
|---|---|---|---|
| 5.1 | The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content. | 🟢 | Lines 2-14: the metadata comment is the first element after <!doctype html>. |
| 5.2 | Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML. | 🟢 | Opening “—” on line 3, closing “—” on line 13; the preamble text on line 2 sits before the opening delimiter. |
| 5.3 | The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet. | 🟢 | Enclosed in an HTML comment; no metadata value is echoed by a rendered element. |
| 5.4 | All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. | 🟢 | All values trimmed; only duration is quoted, and it must be because it contains a colon. |
| 5.5 | The filename of the source ER is stated as “er_filename: [er_filename]” | 🟢 | er_filename: sorbitol_2026-0821-1233_Opus_ER.md (line 4). |
| 5.6 | Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]” | 🟢 | qrs_prompt_version: 26.7.02 (line 5), matching the QRS.md version badge. |
| 5.7 | Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430) | 🟢 | qrs_creation_date: 2026-0821-1425 (line 6), correct YYYY-MMDD-HHMM form. |
| 5.8 | The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]” | 🟢 | qrs_creator_ai_nickname: Opus (line 7). |
| 5.9 | The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT) | 🟢 | “Opus” is a single word with no version or qualifier. |
| 5.10 | The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]” | 🟢 | qrs_creator_ai_fullname: Opus 5 (line 8). |
| 5.11 | The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4) | 🟢 | “Opus 5” is nickname plus version number, no qualifier. |
| 5.12 | The filename of the document is stated as “qrs_filename: [filename of this document]” | 🟢 | qrs_filename: sorbitol_2026-0821-1233_Opus_QRS.html (line 9), matching the file on disk. |
| 5.13 | All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. | 🟢 | Re-verified: no stray whitespace or unnecessary quoting in any of the nine values. |
6. Page Title & Header
| # | Description | Result | Comments |
|---|---|---|---|
| 6.1 | [page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., & for &) |
🟢 | Line 22: “Sorbitol for Health & Longevity - Quick Reference Sheet”, with the ampersand entity-encoded. |
| 6.2 | [header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., & for &) |
🟢 | Line 417: “Sorbitol for Health & Longevity”, matching canonical_topic. |
| 6.3 | [header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY] | 🟢 | Line 421: 08/21/2026, the MM/DD/YYYY form of qrs_creation_date 2026-0821-1425. |
| 6.4 | [header_subline_model] is set to [qrs_creator_ai_fullname] | 🟢 | Line 425: “Opus 5”. |
| 6.5 | No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker. | 🟢 | Header carries only the title and the template subline; no badge, AKA line, version stamp, audit date, or variant marker. |
7. At-A-Glance Section
| # | Description | Result | Comments |
|---|---|---|---|
| 7.1 | [at_a_glance] is dense, execution-oriented summary of the ER Conclusion section |
🟢 | Distilled from the ER Conclusion (lines 462-466): dual identity, laxation, glycaemic advantage, dental benefit, tolerance ceiling, drug-absorption cost. |
| 7.2 | [at_a_glance] is no longer than 60 words | 🟢 | 57 words, verified by word count. |
| 7.3 | Every fact in [at_a_glance] is supported by a distinct passage in the ER. | 🟢 | Each clause maps to a distinct Conclusion passage: dual identity (line 462), stool/glucose/caries (line 462), the 10-20 g threshold (line 464), reduced drug absorption (line 464). |
| 7.4 | It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead | 🟢 | No acronyms; uses “sweetener”, “table sugar”, “loose stool”, “swallowed medicines” rather than specialist terms. |
| 7.5 | It DOES NOT cite specific trials (names, years, sample sizes, p-values) | 🟢 | No trial names, years, sample sizes, or p-values. |
| 7.6 | It DOES NOT cite effect sizes, relative risks, or statistical results | 🟢 | No effect sizes, relative risks, or statistics; “roughly 10 to 20 grams daily” is a dose threshold, not a statistical result. |
8. Contraindications
| # | Description | Result | Comments |
|---|---|---|---|
| 8.1 | The section is derived from the ER Key Interactions & Contraindications section |
🟢 | Drawn from ER lines 289-315. |
| 8.2 | [stop_items] represent the Contraindications from the ER | 🟢 | The five “Populations who should avoid Sorbitol” bullets plus the ER’s one explicit “Absolute contraindication” (sodium/calcium polystyrene sulfonate, ER line 291). |
| 8.3 | Individual [stop_items] are formatted as <li></li> | 🟢 | Six <li> elements inside the [stop_items] span (lines 565-578). |
| 8.4 | Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. | 🟢 | Leading “Anyone with” is dropped and trailing rationale is stripped — e.g. the SORD item drops “who already carries a markedly elevated internal sorbitol load”; the ileus item drops the “(a stalled, paralysed bowel)” gloss. |
| 8.5 | Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). | 🟢 | The decision-bearing qualifiers survive: “(both ALDOB gene copies faulty)”, “(both SORD gene copies faulty)”, “stage 4 or worse”, “with a positive sorbitol breath test”, “with reduced bowel motility”. |
| 8.6 | When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. | N/A | N/A — the ER’s Key Interactions & Contraindications bullets use no ranking notation inside parentheses. |
| 8.7 | The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no population, condition, or scenario for which the intervention should be avoided, deferred, or used only under specialist supervision. |
🟢 | The section is populated, and correctly so — the ER names five populations that should avoid sorbitol plus one absolute contraindication. |
| 8.8 | If the section is left empty, an HTML comment inside the [stop_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g. | N/A | N/A — the section is not empty; [stop_items] carries six contraindications. |
9. Key Interactions
| # | Description | Result | Comments |
|---|---|---|---|
| 9.1 | The section is derived from the ER Key Interactions & Contraindications section |
🟢 | Drawn from ER lines 289-307. |
| 9.2 | [caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications | 🟢 | All eight remaining ER interaction bullets are present; sodium/calcium polystyrene sulfonate is correctly omitted here because it sits in Contraindications. |
| 9.3 | Individual [caution_items] are formatted as <li></li> | 🟢 | Eight <li> elements inside the [caution_items] span (lines 586-595). |
| 9.4 | Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. | 🟢 | Each item is the ER bold label alone; every mitigation and mechanism clause is stripped. |
| 9.5 | Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). | 🟢 | Example drug lists preserved verbatim: “(furosemide, hydrochlorothiazide)”, “(lactulose, polyethylene glycol 3350, magnesium hydroxide)”, “(inulin, fructooligosaccharides)”. |
| 9.6 | When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. | N/A | N/A — the ER’s Key Interactions & Contraindications bullets use no ranking notation inside parentheses. |
| 9.7 | The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no interaction, additive effect, or exposure that changes how the intervention is used. |
🟢 | The section is populated, and correctly so — the ER names nine interactions. |
| 9.8 | If the section is left empty, an HTML comment inside the [caution_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g. | N/A | N/A — the section is not empty; [caution_items] carries eight interactions. |
10. Protocol
| # | Description | Result | Comments |
|---|---|---|---|
| 10.1 | The section is derived from the ER Protocol section |
🟢 | Drawn from the ER Therapeutic Protocol section (lines 337-361). |
| 10.2 | The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section |
🟢 | The dose regimen (line 339), split-dosing rule (line 351) and timing (line 347) are the three decision-bearing implementation aspects in that section. |
| 10.3 | If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. | N/A | N/A — the ER Therapeutic Protocol section supplies three or more distinct actionable aspects; all three sets are used. |
| 10.4 | All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section. |
🟢 | All nine action fields carry substantive ER-derived content; no placeholders. |
11. Time to Effect
| # | Description | Result | Comments |
|---|---|---|---|
| 11.1 | The three sets of [time] items cover the three most important time-to-effect aspects from the ER | 🟢 | Laxative, dental and microbiome effects — the three named in the ER Practical Considerations time-to-effect bullet (line 394). |
| 11.2 | The sets are picked and ordered by the magnitude of the related benefit | 🟢 | Ordered High → Medium → Low by the tier of the associated benefit: laxation (High), dental caries (Medium), microbiome shift (Low). |
| 11.3 | If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. | N/A | N/A — the ER supplies three distinct time-to-effect aspects (laxative, dental, microbiome); all three sets are used. |
| 11.4 | All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER. | 🟢 | All nine time fields carry substantive ER-derived content; the “moderate doses” qualifier on the microbiome cell tracks ER line 181. |
| 11.5 | If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel |
N/A | N/A — the ER does provide time-to-effect information (Practical Considerations, ER line 394). |
12. Benefits
| # | Description | Result | Comments |
|---|---|---|---|
| 12.1 | The section is derived from the ER Expected Benefits section |
🟢 | Drawn from the ER Expected Benefits section (lines 145-199). |
| 12.2 | Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative] | 🟢 | All four spans present (lines 537-555). |
| 12.3 | Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. | 🟢 | Each tier lists ER benefit headings only, joined by semicolons; no magnitudes, mechanisms or citations. |
| 12.4 | Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. | 🟢 | No parenthetical content anywhere in the four benefit spans. |
| 12.5 | If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. | N/A | N/A — all four benefit tiers carry items in the ER Expected Benefits section. |
13. Risks
| # | Description | Result | Comments |
|---|---|---|---|
| 13.1 | The section is derived from the ER Potential Risks & Side Effects section |
🟢 | Drawn from the ER Potential Risks & Side Effects section (lines 217-271). |
| 13.2 | Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative] | 🟢 | All four spans present (lines 607-628). |
| 13.3 | Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. | 🟢 | Each tier lists ER risk headings only; no magnitudes, percentages or study details. |
| 13.4 | Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. | 🟢 | No parenthetical content anywhere in the four risk spans. |
| 13.5 | If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. | N/A | N/A — all four risk tiers carry items in the ER Potential Risks & Side Effects section. |
14. Monitoring
| # | Description | Result | Comments |
|---|---|---|---|
| 14.1 | The section is derived from the ER Monitoring section |
🟢 | Drawn from the ER Monitoring Protocol & Defining Success section (lines 418-433). |
| 14.2 | All measurable/quantifiable biomarkers from the Monitoring section are listed |
🟢 | All eight ER biomarkers present with names, targets and rationales matching the ER table exactly (Bristol score, potassium, sodium, eGFR, fasting glucose, HbA1c, breath test, plasma sorbitol). |
| 14.3 | [monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty. |
🟢 | Populated with the ER’s ongoing-monitoring paragraph condensed (ER line 422): weekly then monthly symptoms, electrolytes at four weeks then six to twelve monthly, HbA1c at three months. |
15. Qualitative Assessment
| # | Description | Result | Comments |
|---|---|---|---|
| 15.1 | The section is derived from the ER Monitoring section |
🟢 | Drawn from the ER qualitative marker list (lines 435-442). |
| 15.2 | All subjective/qualitative biomarkers from the Monitoring section are listed |
🟢 | All six ER qualitative markers present, verbatim. |
Issues 21/08/2026 14:32
Pass rate 100.00%. No issues found.